New Global Criteria Redefine How Doctors Diagnose Vascular Dementia

Vascular cognitive impairment and dementia (VCID) is the second most common cause of dementia globally, yet its diagnosis has long lacked the precision and international consensus applied to Alzheimer's disease. The original VasCog criteria (2014) provided a useful framework but predated major advances in neuroimaging standardization, fluid biomarkers, and understanding of how vascular and neurodegenerative pathologies interact. A decade later, the field needed a comprehensive update.

The VasCog-2-WSO Criteria Consortium — comprising more than 50 leading neurologists, neuropsychologists, and epidemiologists from over 20 countries — undertook a systematic evidence review and iterative expert consensus process to produce revised criteria, now published in JAMA Neurology. The World Stroke Organization (WSO) co-endorsed the effort, underscoring its global clinical ambitions.

The updated criteria retain the core requirement of demonstrable cognitive decline with evidence of cerebrovascular disease but introduce several substantive changes. First, a cleaner severity spectrum is formalized: vascular mild cognitive impairment (VaMCI) and vascular dementia (VaD) are defined with explicit functional and neuropsychological thresholds aligned with contemporary frameworks such as DSM-5 and NIA-AA guidelines. Second, neuroimaging requirements are modernized, with structured integration of STRIVE-2 MRI markers — including white matter hyperintensities, lacunes, microbleeds, enlarged perivascular spaces, and cortical superficial siderosis — enabling more objective, reproducible classification of cerebrovascular burden. Third, the criteria formally recognize mixed VCID, acknowledging that concurrent Alzheimer or other neurodegenerative pathology is the rule rather than the exception in older patients, and providing guidance on how to weight vascular contributions when mixed pathology is present.

The consortium also addresses the cognitive profile expected in VCID, moving away from the historically overemphasized 'subcortical' pattern and recognizing that multiple cognitive domains — including memory, executive function, processing speed, and attention — may be affected depending on lesion location and burden. Guidance is provided for settings where comprehensive neuropsychological testing is unavailable, an important concession to global health equity.

Implications are broad. Standardized criteria will sharpen patient selection for clinical trials of vascular risk factor modification and emerging neuroprotective therapies, potentially accelerating drug development. Clinically, clearer diagnostic boundaries should reduce the underdiagnosis of VCID relative to Alzheimer's disease and improve access to appropriate management, including aggressive vascular risk factor control. The authors acknowledge that prospective validation studies are needed to confirm the criteria's performance characteristics across diverse populations.